GC Biopharma said on the 3rd that it posted 609.5 billion won in consolidation sales in the third quarter of this year. That was up 31% from the same period a year earlier. Quarterly sales surpassed 600 billion won for the first time since its founding.
Operating profit was 29.2 billion won, and net profit was 18.1 billion won. Those fell 26% and 49%, respectively, from a year earlier. The company said sales of the immune deficiency treatment Alglio and prescription drugs expanded.
On a separate basis by institutional sector, sales were 133.6 billion won for plasma fractionation products, 91.9 billion won for vaccines, 170.2 billion won for prescription drugs, and 34 billion won for over-the-counter drugs and consumer healthcare. Hunterase, which treats Hunter syndrome, decreased slightly due to a base effect as overseas supply was concentrated in the first half. Subsidiaries GC Cell, GC MS, and GC Wellbeing recorded sales of 45 billion won, 26.4 billion won, and 42.3 billion won, respectively.